SCHEMBL16612615

SCHEMBL16612615

CC1(C)[C@@H]2C[C@H]1C(C=Cc1ccncc1)=CC2=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.37
NPC1 O15118 4/20 0.37
RAB9A P51151 4/20 0.37
HSP90AA1 P07900 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37
BRD4 O60885 1/20 0.35
CREBBP Q92793 1/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
CYP1A2 P05177 2/20 0.35
HPGD P15428 2/20 0.35
MEN1 O00255 1/20 0.35
ALOX15 P16050 1/20 0.35
CASP1 P29466 1/20 0.35
HBB P68871 1/20 0.35
KMT2A Q03164 1/20 0.35
KDM4E B2RXH2 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16612614 1.00 MAPT (0.37) MAPTNPC1RAB9AHSP90AA1MAPK1
SCHEMBL30284437 1.00 MAPT (0.37) MAPTNPC1RAB9AHSP90AA1MAPK1
SCHEMBL23931228 0.85 CYP2C19 (0.39) MAPTRAB9ABRD4CREBBPSMN1; SMN2
SCHEMBL16612646 0.85 CYP2C19 (0.39) MAPTRAB9ABRD4CREBBPSMN1; SMN2
SCHEMBL23931227 0.85 CYP2C19 (0.39) MAPTRAB9ABRD4CREBBPSMN1; SMN2
SCHEMBL23931226 0.85 CYP2C19 (0.39) MAPTRAB9ABRD4CREBBPSMN1; SMN2
SCHEMBL16612648 0.85 CYP2C19 (0.39) MAPTRAB9ABRD4CREBBPSMN1; SMN2
SCHEMBL30284489 0.84 CYP11B1 (0.43) MAPTNPC1RAB9AHSP90AA1MAPK1
SCHEMBL23931233 0.83 APP (0.36) MAPTNPC1RAB9AMAPK1HTT
SCHEMBL23931237 0.83 APP (0.36) MAPTNPC1RAB9AMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4397304-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES Shin Poong Pharmaceutical Co., Ltd. (KR) 2024-07-10 EP claimed
US-10710951-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2020-07-14 US claimed
EP-2857007-B1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE UNIV KOREA RES & BUS FOUND (KR) 2018-03-28 EP claimed
US-20170166505-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-15 US claimed
US-9603842-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2017-03-28 US claimed
US-20150148362-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2015-05-28 US claimed
EP-2857007-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE Korea University Research and Business Foundation (KR) 2015-04-08 EP claimed
EP-4397304-A1 COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES Shin Poong Pharmaceutical Co., Ltd. (KR) 2024-07-10 EP disclosed
US-10710951-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2020-07-14 US disclosed
EP-2857007-B1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE UNIV KOREA RES & BUS FOUND (KR) 2018-03-28 EP disclosed
US-20170166505-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-15 US disclosed
US-9603842-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2017-03-28 US disclosed
US-20150148362-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2015-05-28 US disclosed
EP-2857007-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE Korea University Research and Business Foundation (KR) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166505-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE CASP3, DCX, BAX MAPT 239/4885NPC1 351/4885RAB9A 3485/4885
US-10710951-B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease CASP3, DCX, BAX MAPT 239/4885NPC1 351/4885RAB9A 3485/4885
US-20150148362-A1 PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE CASP3, DCX, BAX MAPT 239/4885NPC1 351/4885RAB9A 3485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.